Since this activity was originally posted online, the FDA granted accelerated approval for use of trastuzumab deruxtecan to treat adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. For more information about this approval, please visit the FDA website: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2.
FACULTY
Antonio González-Martín, MD, PhD
Director, Cancer Center Clínica Universidad de Navarra
Director of the Department of Medical Oncology
Specialist in Medical Oncology
Madrid, Spain
PROGRAM OVERVIEW
This enduring activity will help you evaluate emerging biomarker-driven, tumor-agnostic approaches toward the management of hard-to-treat, advanced solid tumors that express HER2, including cancers of the endometrium, ovary, cervix, bladder, and biliary tract. This activity will review findings from clinical investigations of HER2-directed therapy to treat these tumors, offer practical guidance on multidisciplinary monitoring and management of treatment-related adverse events in patients receiving a HER2-directed therapy; and provide expert perspectives on the role biomarkers play in this strategy. This interactive program combines didactic instruction with case-based discussions and animations.
TARGET AUDIENCE
This activity is intended for U.S.-based community oncologists involved in the treatment of patients with HER2-positive solid tumors including gynecological, bladder, and biliary tract cancers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Analyze findings from clinical investigations regarding the effectiveness, safety, and patient tolerance of novel HER2-directed ADCs in managing solid tumors with HER2 overexpression
- Assess adverse events linked to the administration of HER2-directed ADCs
- Evaluate the available data on prospective predictive biomarkers for HER2-directed ADCs for HER2-expressing solid tumors
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Antonio González-Martín MD | Consultant | Alkermes, Amgen, AstraZeneca, Clovis, Genmab, GlaxoSmithKline, HederaDx, Immunogen, Kartos, Karyopharm, Illumina, Mersana Therapeutics, MSD, Novartis, Novocure, Oncoinvent, PharmaMar, Roche, SOTIO Biotech, SUTRO Biopharma, Seagen, Takeda Pharmaceuticals, and Tubulis |
| Contracted Research | GlaxoSmithKline, Roche Instituto de Salud Carlos iii, and AECC Pharmaceuticals | |
| Speakers Bureau | AstraZeneca, Clovis, GlaxoSmithKline, Immunogen, Mersana Therapeutics, MSD, Novocure, PharmaMar, Roche, and Takeda Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and a nurse practitioner.
Individuals in Control of the Content of the Activity
The individuals in control of the content of the activity reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Kim L. Farina, Medical Director for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: March 05, 2024
EXPIRATION DATE: March 05, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
